top of page

Representatives Don Davis (D-NC), Brett Guthrie (R-KY), and Greg Murphy (R-NC) introduced H.R. 7174, the Ensuring Pathways to Innovative Cures (EPIC) Act, advancing the top legislative priority for Incubate and life sciences venture capital. This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large molecule medicines. Current law affords small-molecule drugs just 9 years of exemption, while large molecule biologics receive 13 years.  

The EPIC Act prioritizes the patients of Kentucky’s 2nd District by eliminating the Small Molecule penalty. 

EPIC Act Resources
In the News
Congress must fix the IRA’s small molecule penalty
The IRA Is Already Curtailing Small Molecule Drug Development. Here’s How to Reverse That.
bottom of page